05.16.11
Research conducted at the University of Utah Brain Institute revealed that individuals receiving Cognizin citicoline, from Kyowa Hakko, at a dose of 250 mg showed improved attention and a better ability to produce correct responses in performance testing. Participants who were administered either the 250 mg or the 500 mg dose of Cognizin produced nearly identical results when compared to the placebo group, confirming that 250 mg is an efficacious dose for producing improvements in attention.
Findings were presented by Erin McGlade, PhD, Research Fellow at the Brain Institute, at the 66th Annual Meeting of the Society of Biological Psychiatry in San Francisco.
Subjects in this double-blind, placebo-controlled three-arm study designed to evaluate the effectiveness of Cognizin citicoline on attentional function included 60 healthy women ages 40-60. Participants were divided into three groups of 20 and then completed a clinical screening visit, including a medical exam. After enrollment, each subject began supplementation with a daily oral dose of either 250 mg (low dose) or 500 mg (high dose) of Cognizin citicoline or placebo for 28 days.
Participants were then evaluated with the Continuous Performance Test II (CPT-II), a measure sensitive to attentional function. Results after supplementation showed that individuals receiving either the low or high dose of Cognizin Citicoline produced fewer commission errors on the CPT-II compared to the placebo group. Specifically, individuals in the two Cognizin citicoline supplemented groups made fewer errors when responding to non-target stimuli. These findings suggest improved attention when required to inhibit incorrect responses. For further information: www.cognizin.com
Findings were presented by Erin McGlade, PhD, Research Fellow at the Brain Institute, at the 66th Annual Meeting of the Society of Biological Psychiatry in San Francisco.
Subjects in this double-blind, placebo-controlled three-arm study designed to evaluate the effectiveness of Cognizin citicoline on attentional function included 60 healthy women ages 40-60. Participants were divided into three groups of 20 and then completed a clinical screening visit, including a medical exam. After enrollment, each subject began supplementation with a daily oral dose of either 250 mg (low dose) or 500 mg (high dose) of Cognizin citicoline or placebo for 28 days.
Participants were then evaluated with the Continuous Performance Test II (CPT-II), a measure sensitive to attentional function. Results after supplementation showed that individuals receiving either the low or high dose of Cognizin Citicoline produced fewer commission errors on the CPT-II compared to the placebo group. Specifically, individuals in the two Cognizin citicoline supplemented groups made fewer errors when responding to non-target stimuli. These findings suggest improved attention when required to inhibit incorrect responses. For further information: www.cognizin.com